CagriSema Guide
CagriSema: semaglutide plus amylin, and what trials report
2 in 1
GLP-1 + amylin analog, weekly
~23%
phase 3 average loss, 68 wks
Not yet
approved; filings in progress
CagriSema is Novo Nordisk's next act after Wegovy: a once-weekly injection combining semaglutide 2.4 mg with cagrilintide, an analog of amylin, the satiety hormone insulin's beta cells co-release. The pairing attacks appetite through two systems at once, and the phase 3 REDEFINE-1 trial reported average weight loss around 22.7% at 68 weeks, in tirzepatide's territory and above semaglutide alone. It is not approved: regulatory filings are in progress, and everything here reflects trial reports. The side effects reported so far are the familiar GI list, led by the nausea that amylin analogs are independently known for.
Highlights
Key takeaways
- 01
CagriSema is investigational: filings are underway and everything known comes from the trial program, not prescribing information.
- 02
The mechanism is a genuine pairing: semaglutide's GLP-1 signal plus cagrilintide's amylin signal, two different satiety systems engaged at once.
- 03
REDEFINE-1 (obesity, 68 weeks): ~22.7% average weight loss, versus ~16.1% for semaglutide alone and ~11.8% for cagrilintide alone in the same trial.
- 04
A notable trial detail: flexible dosing let participants settle below maximum doses, and many did while still averaging strong results.
- 05
Reported side effects were class-standard GI events, mostly mild to moderate, escalation-focused; amylin analogs bring their own nausea contribution.
- 06
In diabetes (REDEFINE-2), average loss ran ~13.7%, consistent with the usual diabetes-population discount.
CagriSema at a glance: what trials have reported
| Aspect | What phase 3 reported | Context |
|---|---|---|
| Weight loss (obesity) | ~22.7% average at 68 wks | REDEFINE-1; flexible dosing protocol |
| vs components alone | Sema ~16.1%, cagrilintide ~11.8% | Same trial, same duration |
| Weight loss (with T2D) | ~13.7% average | REDEFINE-2 |
| Common side effects | Nausea, vomiting, constipation, diarrhea | Mostly mild to moderate, escalation-focused |
| Dosing | Once weekly, dual-chamber pen | Semaglutide 2.4 mg + cagrilintide 2.4 mg targets |
| Status | Regulatory filings in progress | No approval yet anywhere |
Drawn from REDEFINE program communications and presentations available at writing. Investigational figures shift as full datasets publish; nothing here is prescribing information or a reason to seek the combination outside trials.
What is CagriSema, and why amylin?
Amylin is a hormone co-released with insulin after meals: it slows gastric emptying, promotes satiety, and quiets glucagon, a satiety channel distinct from the incretin system GLP-1s use. Cagrilintide is a long-acting amylin analog, and CagriSema packages it with semaglutide 2.4 mg in one weekly injection.
The bet is additive appetite control through parallel systems, the same combination logic as tirzepatide's dual agonism, executed with two molecules instead of one.
What did REDEFINE actually show?
REDEFINE-1 (obesity, 68 weeks) reported ~22.7% average weight loss for the combination, against ~16.1% for semaglutide alone and ~11.8% for cagrilintide alone in the same protocol. That places CagriSema in tirzepatide's territory and confirms the pairing adds real effect over either component.
One much-discussed detail: the protocol allowed flexible dosing, and a substantial share of participants settled below the maximum doses while the trial still averaged those results, an encouraging sign for real-world tolerability management. REDEFINE-2, in type 2 diabetes, averaged ~13.7%, the usual diabetes-population discount.
What side effects did the trials report?
The reported profile is the class profile: gastrointestinal events led (nausea, vomiting, constipation, diarrhea), mostly mild to moderate, concentrated during escalation, with discontinuation rates in the familiar single digits. Amylin analogs carry their own well-known nausea contribution, so the combination's GI load was a central question; flexible dosing appears to have been part of the answer.
Full peer-reviewed safety datasets are still publishing, and any label will refine this picture. Until then, treat the summary as directionally reliable and detail-provisional.
Cautions worth carrying
Expect the incretin-class cautions to carry over: pancreatitis vigilance, gallbladder risk with rapid loss, hypoglycemia in combination with insulin or sulfonylureas, the thyroid C-cell warning lineage, and stopping ahead of pregnancy.
And the standing market caution: until approval, anything sold as CagriSema or cagrilintide online is unregulated gray-market chemistry. A dual-molecule product is even harder to fake safely than a single one; the legitimate version arrives through pharmacies or not at all.
Worth knowing before the headlines sweep you up
- CagriSema is investigational: no approval, no prescribing information yet
- Online cagrilintide or CagriSema is gray-market chemistry with zero oversight
- Amylin analogs add their own nausea; escalation pacing matters
- Class cautions (pancreatitis, gallbladder, thyroid C-cell) are expected to apply
- Trial results used flexible dosing; headline numbers assume managed titration
- Approved options exist today; waiting untreated has its own costs
When could it arrive, and what now?
Filings are with regulators; decisions and launch timing follow their clocks, with the usual staggering by country. If approved, expect positioning directly against Zepbound, with pricing and supply setting the real-world pecking order.
Meanwhile the approved options are the treatment, and they are strong. If CagriSema eventually suits you, every habit that matters (protein floor, training, hydration, honest tracking) transfers completely from whatever you and your prescriber choose today.
FAQ
Frequently asked questions
What is CagriSema?
An investigational once-weekly injection combining semaglutide 2.4 mg with cagrilintide, a long-acting amylin analog, engaging two satiety systems at once. Phase 3 reported ~22.7% average weight loss at 68 weeks; it is not yet approved.
Is CagriSema better than Zepbound?
No head-to-head exists. REDEFINE-1's ~22.7% average sits in the same territory as tirzepatide's obesity results, with different trial designs making precise comparison impossible. If approved, they will compete directly and access will decide much.
What are CagriSema's side effects?
Trials report the class-standard GI list (nausea, vomiting, constipation, diarrhea), mostly mild to moderate and escalation-focused, with amylin's known nausea contribution managed partly through flexible dosing. Full safety datasets are still publishing.
When will CagriSema be available?
Regulatory filings are in progress; approval decisions and launch timing follow. Anything sold under these names before approval is unregulated and unsafe to use.
Track your GLP-1 journey on one quiet line.
Log your shot, injection site, meals, and side-effect severity together, and walk into your next appointment with a week-by-week picture instead of a guess.
Sources
- 1.REDEFINE-1 and REDEFINE-2 phase 3 results: sponsor communications and conference presentations. Find on PubMed ↗
- 2.Published phase 2 data on cagrilintide and the cagrilintide-semaglutide combination. Find on PubMed ↗
- 3.Reviews of amylin physiology and amylin-analog therapeutics. Find on PubMed ↗
This guide is for general education and is not medical advice. It doesn't account for your personal medical history, other medications, or your individual situation, and it doesn't replace a conversation with your doctor or pharmacist. Do not start, stop, or change the dose of GLP-1 or any medication based on what you read here. If you think you have a medical emergency, call your local emergency number. DoseLog is a tracking app; drug and company names are used factually under nominative fair use, and DoseLog is not affiliated with, endorsed by, or sponsored by any manufacturer mentioned.
Keep reading
Survodutide Guide
Survodutide: the GLP-1/glucagon dual agonist in late trials
Mazdutide Guide
Mazdutide: the GLP-1/glucagon agonist approved first in China
Amycretin Guide
Amycretin: the GLP-1/amylin combo in oral and injectable trials
Pemvidutide Guide
Pemvidutide: the GLP-1/glucagon agonist aimed at fat and liver